Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)
B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Sample Characteristics

1. N
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)
B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
Total
2. Baseline population
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)
B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderMean visual acuity, logMAR (SD)
  • All Participants
  • end of study
CategoricalVision disorderMean intraocular pressure (IOP), mmHg (SD)
  • All Participants
  • end of study
CategoricalVision disorderMean visual field mean deviation (SD)
  • All Participants
  • end of study
CategoricalVision disorderDisease progression
  • All Participants
  • end of study
ContinuousHarm/adverse eventAny serious adverse event
  • All Participants
  • end of study
ContinuousHarm/adverse eventOcular serious adverse event
  • All Participants
  • end of study
CategoricalVision disorderEyes at target intraocular pressure (IOP)
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (Mean visual acuity, logMAR (SD))

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Mean
Odds Ratio (OR)
Standard deviation
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Vision disorder (Mean intraocular pressure (IOP), mmHg (SD))

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Mean
Odds Ratio (OR)
Standard deviation
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Vision disorder (Mean visual field mean deviation (SD))

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Mean
Odds Ratio (OR)
Standard deviation
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Vision disorder (Disease progression)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Mean
Odds Ratio (OR)
Standard deviation
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Vision disorder (Eyes at target intraocular pressure (IOP))

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Mean
Odds Ratio (OR)
Standard deviation
95% CI low (OR)
Percentage
95% CI high (OR)
p value
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Continuous


Harm/adverse event (Any serious adverse event)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Percentage
Mean Difference (MD)
95% CI low (MD)
95% CI high (MD)
SD (MD)
p value (MD)
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)

Harm/adverse event (Ocular serious adverse event)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)
end of study
Percentage
Mean Difference (MD)
95% CI low (MD)
95% CI high (MD)
SD (MD)
p value (MD)
Within Arm ComparisonsNet Comparisons
A. Selective laser trabeculoplasty (SLT): 100 spots over 360°; if target intraocular pressure (IOP) not reached, second SLT allowed (n=356)B. Medical therapy: first line prostaglandin analogues, then β blockers, then topical carbonic anhydrase inhibitors or alpha agonists (n=362)